IDRA Annual FCF
-$24.60 M
+$9.18 M+27.18%
31 December 2021
Summary:
As of February 5, 2025, IDRA annual free cash flow is -$24.60 million, with the most recent change of +$9.18 million (+27.18%) on December 31, 2021. During the last 3 years, it has risen by +$27.39 million (+52.69%).IDRA Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IDRA Quarterly FCF
-$3.20 M
+$327.00 K+9.28%
30 September 2022
Summary:
As of February 5, 2025, IDRA quarterly free cash flow is -$3.20 million, with the most recent change of +$327.00 thousand (+9.28%) on September 30, 2022. Over the past year, it has increased by +$1.50 million (+31.88%).IDRA Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IDRA TTM FCF
-$15.34 M
+$1.50 M+8.89%
30 September 2022
Summary:
As of February 5, 2025, IDRA TTM free cash flow is -$15.34 million, with the most recent change of +$1.50 million (+8.89%) on September 30, 2022. Over the past year, it has increased by +$12.78 million (+45.45%).IDRA TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IDRA Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +27.2% | +31.9% | +45.5% |
| 3 y3 years | +52.7% | +70.5% | +65.5% |
| 5 y5 years | +55.6% | +73.1% | +65.5% |
IDRA Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -206.2% | -109.1% | -166.2% |
Idera Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$3.20 M(-9.3%) | -$15.34 M(-8.9%) |
| June 2022 | - | -$3.52 M(-22.8%) | -$16.84 M(-14.0%) |
| Mar 2022 | - | -$4.57 M(+12.7%) | -$19.57 M(-20.4%) |
| Dec 2021 | -$24.60 M(-27.2%) | -$4.05 M(-13.7%) | -$24.60 M(-12.5%) |
| Sept 2021 | - | -$4.70 M(-25.0%) | -$28.13 M(-7.9%) |
| June 2021 | - | -$6.26 M(-34.7%) | -$30.52 M(-6.4%) |
| Mar 2021 | - | -$9.59 M(+26.5%) | -$32.62 M(-3.4%) |
| Dec 2020 | -$33.78 M(-24.1%) | -$7.58 M(+6.9%) | -$33.78 M(-7.5%) |
| Sept 2020 | - | -$7.09 M(-15.1%) | -$36.53 M(-9.3%) |
| June 2020 | - | -$8.35 M(-22.3%) | -$40.27 M(-3.9%) |
| Mar 2020 | - | -$10.76 M(+4.1%) | -$41.90 M(-5.9%) |
| Dec 2019 | -$44.51 M(-14.4%) | -$10.33 M(-4.7%) | -$44.51 M(-2.5%) |
| Sept 2019 | - | -$10.84 M(+8.6%) | -$45.66 M(-2.1%) |
| June 2019 | - | -$9.98 M(-25.3%) | -$46.64 M(-7.8%) |
| Mar 2019 | - | -$13.36 M(+16.4%) | -$50.59 M(-2.7%) |
| Dec 2018 | -$51.99 M(-6.3%) | -$11.48 M(-2.9%) | -$51.99 M(-0.2%) |
| Sept 2018 | - | -$11.82 M(-15.2%) | -$52.12 M(-0.1%) |
| June 2018 | - | -$13.93 M(-5.6%) | -$52.18 M(-0.7%) |
| Mar 2018 | - | -$14.76 M(+27.2%) | -$52.55 M(-5.3%) |
| Dec 2017 | -$55.47 M(+93.9%) | -$11.61 M(-2.3%) | -$55.47 M(+41.7%) |
| Sept 2017 | - | -$11.88 M(-16.9%) | -$39.15 M(+3.6%) |
| June 2017 | - | -$14.30 M(-19.1%) | -$37.80 M(+13.4%) |
| Mar 2017 | - | -$17.68 M(-475.5%) | -$33.34 M(+16.5%) |
| Dec 2016 | -$28.61 M(-34.5%) | $4.71 M(-144.7%) | -$28.61 M(-31.9%) |
| Sept 2016 | - | -$10.54 M(+7.1%) | -$42.04 M(-3.5%) |
| June 2016 | - | -$9.84 M(-24.0%) | -$43.55 M(-0.7%) |
| Mar 2016 | - | -$12.95 M(+48.4%) | -$43.84 M(+0.3%) |
| Dec 2015 | -$43.71 M(+34.9%) | -$8.72 M(-27.6%) | -$43.71 M(-2.2%) |
| Sept 2015 | - | -$12.04 M(+18.9%) | -$44.70 M(+8.8%) |
| June 2015 | - | -$10.13 M(-20.9%) | -$41.07 M(+9.2%) |
| Mar 2015 | - | -$12.81 M(+31.9%) | -$37.61 M(+16.0%) |
| Dec 2014 | -$32.41 M(+89.0%) | -$9.71 M(+15.5%) | -$32.41 M(+19.3%) |
| Sept 2014 | - | -$8.41 M(+26.0%) | -$27.17 M(+16.0%) |
| June 2014 | - | -$6.68 M(-12.3%) | -$23.43 M(+11.2%) |
| Mar 2014 | - | -$7.61 M(+70.4%) | -$21.06 M(+22.8%) |
| Dec 2013 | -$17.15 M(-13.9%) | -$4.47 M(-4.4%) | -$17.15 M(+2.1%) |
| Sept 2013 | - | -$4.67 M(+8.5%) | -$16.80 M(-0.2%) |
| June 2013 | - | -$4.31 M(+16.4%) | -$16.84 M(-5.6%) |
| Mar 2013 | - | -$3.70 M(-10.2%) | -$17.84 M(-10.4%) |
| Dec 2012 | -$19.92 M(+3.6%) | -$4.12 M(-12.6%) | -$19.92 M(+2.8%) |
| Sept 2012 | - | -$4.71 M(-11.1%) | -$19.38 M(+1.5%) |
| June 2012 | - | -$5.30 M(-8.3%) | -$19.08 M(+2.0%) |
| Mar 2012 | - | -$5.78 M(+61.3%) | -$18.72 M(-2.6%) |
| Dec 2011 | -$19.21 M(-2.2%) | -$3.58 M(-18.9%) | -$19.21 M(-19.6%) |
| Sept 2011 | - | -$4.42 M(-10.5%) | -$23.89 M(+2.3%) |
| June 2011 | - | -$4.93 M(-21.4%) | -$23.35 M(-0.0%) |
| Mar 2011 | - | -$6.28 M(-24.0%) | -$23.36 M(+18.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2010 | -$19.65 M(+25.0%) | -$8.26 M(+112.7%) | -$19.65 M(+13.8%) |
| Sept 2010 | - | -$3.88 M(-21.5%) | -$17.27 M(-2.9%) |
| June 2010 | - | -$4.95 M(+93.0%) | -$17.78 M(+37.6%) |
| Mar 2010 | - | -$2.56 M(-56.4%) | -$12.93 M(-17.7%) |
| Dec 2009 | -$15.71 M(-167.8%) | -$5.87 M(+33.5%) | -$15.71 M(+13.3%) |
| Sept 2009 | - | -$4.40 M(+4843.8%) | -$13.87 M(+6.8%) |
| June 2009 | - | -$89.00 K(-98.3%) | -$12.99 M(-24.3%) |
| Mar 2009 | - | -$5.35 M(+32.7%) | -$17.15 M(-174.0%) |
| Dec 2008 | $23.17 M(-233.2%) | -$4.03 M(+14.6%) | $23.17 M(+6.3%) |
| Sept 2008 | - | -$3.52 M(-17.2%) | $21.80 M(+3.3%) |
| June 2008 | - | -$4.25 M(-112.2%) | $21.10 M(-6.0%) |
| Mar 2008 | - | $34.97 M(-747.2%) | $22.45 M(-229.1%) |
| Dec 2007 | -$17.39 M(-792.9%) | -$5.40 M(+28.1%) | -$17.39 M(-795.3%) |
| Sept 2007 | - | -$4.22 M(+45.7%) | $2.50 M(-0.7%) |
| June 2007 | - | -$2.90 M(-40.6%) | $2.52 M(+150.1%) |
| Mar 2007 | - | -$4.87 M(-133.6%) | $1.01 M(-59.9%) |
| Dec 2006 | $2.51 M(-123.3%) | $14.49 M(-444.9%) | $2.51 M(-115.9%) |
| Sept 2006 | - | -$4.20 M(-4.7%) | -$15.75 M(+45.3%) |
| June 2006 | - | -$4.41 M(+30.7%) | -$10.84 M(+0.6%) |
| Mar 2006 | - | -$3.37 M(-10.5%) | -$10.77 M(+0.2%) |
| Dec 2005 | -$10.76 M(-19.4%) | -$3.77 M(-633.6%) | -$10.76 M(+8.3%) |
| Sept 2005 | - | $705.90 K(-116.3%) | -$9.93 M(-30.3%) |
| June 2005 | - | -$4.34 M(+29.4%) | -$14.26 M(+7.4%) |
| Mar 2005 | - | -$3.35 M(+14.0%) | -$13.28 M(-0.6%) |
| Dec 2004 | -$13.35 M(-7.5%) | -$2.94 M(-18.6%) | -$13.35 M(-7.6%) |
| Sept 2004 | - | -$3.62 M(+7.5%) | -$14.46 M(+4.4%) |
| June 2004 | - | -$3.36 M(-1.9%) | -$13.85 M(-1.3%) |
| Mar 2004 | - | -$3.43 M(-15.3%) | -$14.04 M(-2.7%) |
| Dec 2003 | -$14.43 M(+27.1%) | -$4.05 M(+34.5%) | -$14.43 M(+3.3%) |
| Sept 2003 | - | -$3.01 M(-15.2%) | -$13.97 M(+4.7%) |
| June 2003 | - | -$3.55 M(-7.2%) | -$13.35 M(+0.4%) |
| Mar 2003 | - | -$3.83 M(+6.7%) | -$13.29 M(+17.1%) |
| Dec 2002 | -$11.35 M(-187.2%) | -$3.59 M(+50.2%) | -$11.35 M(+5.5%) |
| Sept 2002 | - | -$2.39 M(-31.7%) | -$10.76 M(+29.2%) |
| June 2002 | - | -$3.50 M(+85.6%) | -$8.33 M(-162.0%) |
| Mar 2002 | - | -$1.88 M(-37.1%) | $13.43 M(+3.1%) |
| Dec 2001 | $13.03 M(-266.2%) | -$2.99 M(-6338.5%) | $13.03 M(-5.7%) |
| Sept 2001 | - | $48.00 K(-99.7%) | $13.81 M(+16.9%) |
| June 2001 | - | $18.26 M(-899.0%) | $11.82 M(-248.2%) |
| Mar 2001 | - | -$2.29 M(+3.5%) | -$7.98 M(+2.2%) |
| Dec 2000 | -$7.84 M(-8.9%) | -$2.21 M(+13.3%) | -$7.80 M(+39.4%) |
| Sept 2000 | - | -$1.95 M(+27.0%) | -$5.60 M(+53.4%) |
| June 2000 | - | -$1.53 M(-27.3%) | -$3.65 M(+72.7%) |
| Mar 2000 | - | -$2.11 M | -$2.11 M |
| Dec 1999 | -$8.60 M(-62.9%) | - | - |
| Dec 1998 | -$23.15 M(-60.5%) | - | - |
| Dec 1997 | -$58.66 M(+14.9%) | - | - |
| Dec 1996 | -$51.04 M | - | - |
FAQ
- What is Idera Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Idera Pharmaceuticals?
- What is Idera Pharmaceuticals annual FCF year-on-year change?
- What is Idera Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Idera Pharmaceuticals?
- What is Idera Pharmaceuticals quarterly FCF year-on-year change?
- What is Idera Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Idera Pharmaceuticals?
- What is Idera Pharmaceuticals TTM FCF year-on-year change?
What is Idera Pharmaceuticals annual free cash flow?
The current annual FCF of IDRA is -$24.60 M
What is the all time high annual FCF for Idera Pharmaceuticals?
Idera Pharmaceuticals all-time high annual free cash flow is $23.17 M
What is Idera Pharmaceuticals annual FCF year-on-year change?
Over the past year, IDRA annual free cash flow has changed by +$9.18 M (+27.18%)
What is Idera Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of IDRA is -$3.20 M
What is the all time high quarterly FCF for Idera Pharmaceuticals?
Idera Pharmaceuticals all-time high quarterly free cash flow is $34.97 M
What is Idera Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, IDRA quarterly free cash flow has changed by +$1.50 M (+31.88%)
What is Idera Pharmaceuticals TTM free cash flow?
The current TTM FCF of IDRA is -$15.34 M
What is the all time high TTM FCF for Idera Pharmaceuticals?
Idera Pharmaceuticals all-time high TTM free cash flow is $23.17 M
What is Idera Pharmaceuticals TTM FCF year-on-year change?
Over the past year, IDRA TTM free cash flow has changed by +$12.78 M (+45.45%)